NASDAQ: TELO
Telomir Pharmaceuticals, Inc. Common Stock
Healthcare · Biotechnology
After hours: $1.16(0%) · as of 7:34 PM ET
Market Cap
$39.88M
52w High
$2.09
52w Low
$0.89
P/E
-3.95
Volume
11.35K
Outstanding Shares
34.38M
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock fell 30.54% over the last year. Free cash flow declined 15.13% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Free cash flow fell 15.13% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Sep 2, 2026
Q3 FY26 · EPS est -$0.07 · Revenue est —
View